What question did this study set out to answer?

To report the clinical presentation, diagnostic findings, and treatment outcome of targeted vemurafenib therapy in a patient with BRAF V600E-mutated Erdheim-Chester disease.

October 12, 2023Journal of Medical Case ReportsOpen Access

An effective treatment in Erdheim Chester disease: vemurafenib: a case report

View Full Paper

Ask AI

Bookmark

Authors

EBErsin BozanMinistry of Health TDTahir DarçınAnkara Onkoloji Eğitim ve Araştırma Hastanesi SYSamet YamanMinistry of Health

Discussion

Member takes

Implication

Case report demonstrates dramatic clinical response to vemurafenib in Erdheim-Chester disease, highlighting the therapeutic value of targeted BRAF inhibition.

Key Points

To report the clinical presentation, diagnostic findings, and treatment outcome of targeted vemurafenib therapy in a patient with BRAF V600E-mutated Erdheim-Chester disease.
Clinical and diagnostic workup of a 47-year-old female presenting with weakness, fatigue, progressive knee pain, and left eye ptosis.
Pathological confirmation of Erdheim-Chester disease via bone biopsy and molecular detection of the BRAF V600E mutation.
Implementation and longitudinal monitoring of targeted kinase inhibitor therapy with vemurafenib.
Bone biopsy and molecular analysis confirmed a diagnosis of non-Langerhans cell histiocytosis harboring the BRAF V600E mutation.
Targeted treatment with vemurafenib resulted in a dramatic qualitative clinical response and substantial symptom resolution across multisystem disease manifestations.

Cite This Study

Bozan et al. (2023) studied this question.

synapsesocial.com/papers/6a8bb8a122230c1854fb4c56 https://doi.org/10.1186/s13256-023-04153-z

View Full Paper

Ask AI

Bookmark

October 12, 2023Journal of Medical Case ReportsOpen Access

An effective treatment in Erdheim Chester disease: vemurafenib: a case report

View Full Paper

Ask AI

Bookmark

Authors

EBErsin BozanMinistry of Health TDTahir DarçınAnkara Onkoloji Eğitim ve Araştırma Hastanesi SYSamet YamanMinistry of Health

Discussion

Member takes

Implication

Case report demonstrates dramatic clinical response to vemurafenib in Erdheim-Chester disease, highlighting the therapeutic value of targeted BRAF inhibition.

Key Points

To report the clinical presentation, diagnostic findings, and treatment outcome of targeted vemurafenib therapy in a patient with BRAF V600E-mutated Erdheim-Chester disease.
Clinical and diagnostic workup of a 47-year-old female presenting with weakness, fatigue, progressive knee pain, and left eye ptosis.
Pathological confirmation of Erdheim-Chester disease via bone biopsy and molecular detection of the BRAF V600E mutation.
Implementation and longitudinal monitoring of targeted kinase inhibitor therapy with vemurafenib.
Bone biopsy and molecular analysis confirmed a diagnosis of non-Langerhans cell histiocytosis harboring the BRAF V600E mutation.
Targeted treatment with vemurafenib resulted in a dramatic qualitative clinical response and substantial symptom resolution across multisystem disease manifestations.

Cite This Study

Bozan et al. (2023) studied this question.

synapsesocial.com/papers/6a8bb8a122230c1854fb4c56 https://doi.org/10.1186/s13256-023-04153-z

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark